July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Safety Analysis of a Sustained Release Travoprost Intracameral Hydrogel Implant in Beagle Dogs
Author Affiliations & Notes
  • Arthur Driscoll
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Charles D Blizzard
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Ankita Desai
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Shelby D'Abbraccio
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Jennifer Langh
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Jessica Mangano
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Noah Buff
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Jamie Lynne Metzinger
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Michael H Goldstein
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Ann Gelormini
    R&D, Ocular Therapeutix, Bedford, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Arthur Driscoll, Ocular Therapeutix (E); Charles Blizzard, Ocular Therapeutix (E); Ankita Desai, Ocular Therapeutix (E); Shelby D'Abbraccio, Ocular Therapeutix (E); Jennifer Langh, Ocular Therapeutix (E); Jessica Mangano, Ocular Therapeutix (E); Noah Buff, Ocular Therapeutix (E); Jamie Lynne Metzinger, Ocular Therapeutix (E); Michael Goldstein, Ocular Therapeutix (E); Ann Gelormini, Ocular Therapeutix (E)
  • Footnotes
    Support  This trial was supported in full by Ocular Therapeutix.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1250. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Arthur Driscoll, Charles D Blizzard, Ankita Desai, Shelby D'Abbraccio, Jennifer Langh, Jessica Mangano, Noah Buff, Jamie Lynne Metzinger, Michael H Goldstein, Ann Gelormini; Safety Analysis of a Sustained Release Travoprost Intracameral Hydrogel Implant in Beagle Dogs. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1250.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the safety of an intracameral hydrogel implant, OTX-TIC, formulated for zero-order travoprost release over 4-months.

Methods : OTX-TIC was injected using a 27 g needle into the anterior chamber of beagle dogs (n=16; 32 eyes); half of the animals received a control article in the right eye and the left eye was untreated. All animals were clinically observed daily, with local toxicity evaluation based on anterior segment ophthalmic examinations, fundus evaluations, intraocular pressure (IOP), measurement of corneal thickness, changes in pupil diameter and histopathology of ophthalmic tissues. Systemic toxicity was evaluated based on survival, clinical signs, body weight, quantitative food consumption, clinical pathology and macroscopic and microscopic findings. Plasma samples were collected pre- and post-dose (1 and 4 hours, and at 2, 4, 6, 8, 10, 12, 14 and 16 weeks) and were analyzed for travoprost (ester and acid) by LC/MS/MS (LOQ 0.5 ng/mL).

Results : Test and placebo articles were well-tolerated over 4 months. No systemic toxicity, changes in corneal thickness, or macro or microscopic findings on histopathology were observed. Plasma values of travoprost were below the LOQ for all samples. The major ocular findings were mild conjunctiva redness (a known effect of travoprost), and mild conjunctival discharge (considered to be injection related and observed in both test and control article treated animals). All mild ocular findings resolved over the course of the study. IOP in eyes injected with OTX-TIC was significantly lower (P<0.05) than in eyes injected with control articles or untreated eyes on Day 120; Correspondingly, pupil size was also decreased in the test articles treated eyes.

Conclusions : These findings are consistent with the known IOP lowering efficacy and miotic response of travoprost. There was no significant difference in corneal thickness between all groups. The histopathological evaluation indicated there were no macroscopic or microscopic findings related to the test article, after 4 months of test article exposure in the eyes of beagle dogs. The presence of the test articles was well tolerated. Results showed no systemic toxicity after administration.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×